Search

Your search keyword '"Raita Heiskanen"' showing total 10 results
Start Over Author "Raita Heiskanen" Publication Year Range Last 3 years

Refine your results

10 results on '"Raita Heiskanen"'

1. Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

PDF file - 100K, PBMCs were isolated from patients before and circa one month after treatment and pulsed with an adenovirus-derived peptide pool and analyzed with IFN-gamma ELISPOT.

Published
2023

2. Data from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

Purpose: Multiple injections of oncolytic adenovirus could enhance immunologic response. In the first part of this article, the focus was on immunologic aspects. Sixty patients previously naïve to oncolytic virus and who had white blood cells available were treated. Thirty-nine of 60 were assessed after a single virus administration, whereas 21 of 60 received a “serial treatment” consisting of three injections within 10 weeks. In the second part, we focused on 115 patients treated with a granulocyte macrophage colony-stimulating factor (GM–CSF)–coding capsid chimeric adenovirus, CGTG-102.Results: Following serial treatment, both increase and decrease in antitumor T cells in blood were seen more frequently, findings which are compatible with induction of T-cell immunity and trafficking of T cells to tumors, respectively. Safety was good in both groups. In 115 patients treated with CGTG-102 (Ad5/3-D24-GMCSF), median overall survival was 111 days following single and 277 days after serial treatment in nonrandomized comparison. Switching the virus capsid for avoiding neutralizing antibodies in a serial treatment featuring three different viruses did not impact safety or efficacy. A correlation between antiviral and antitumor T cells was seen (P = 0.001), suggesting that viral oncolysis can result in epitope spreading and breaking of tumor-associated immunologic tolerance. Alternatively, some patients may be more susceptible to induction of T-cell immunity and/or trafficking.Conclusions: These results provide the first human data linking antiviral immunity with antitumor immunity, implying that oncolytic viruses could have an important role in cancer immunotherapy. Clin Cancer Res; 19(10); 2734–44. ©2013 AACR.

Published
2023

3. Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

PDF file - 62K, Adverse reactions of all CGTG-102 patients.

Published
2023

4. Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

PDF file - 67K, Adverse reactions in patients na�ve to oncolytic adenovirus.

Published
2023

6. Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

PDF file - 889K, Individual anti-tumor (survivin) and anti-viral (Ad5) ELISPOT results in single (A) and serial (B) treated patients.

Published
2023

7. Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

PDF file - 71K, Characteristics of patients na�ve to oncolytic adenovirus.

Published
2023

8. Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

PDF file - 94K, The phenotypic panel of circulating white blood cells.

Published
2023

9. Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

PDF file - 95K, A panel of proinflammatory cytokines was analyzed to evaluate the safety of treatment.

Published
2023

10. Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

Author

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, and Anna Kanerva

Abstract

PDF file - 141K, Example of progressive inflammation in serial treatment.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results